Rates of bleeding were similar in the two groups ( 21 [ 38 % ] in the rituximab group vs 27 [ 50 % ] in the placebo group ; p = 008 ) as were rates of infection ( 22 [ 40 % ] vs 13 [ 24 % ] ; p = 009 ) .